» Articles » PMID: 23681229

Loss of Connective Tissue Growth Factor As an Unfavorable Prognosis Factor Activates MiR-18b by PI3K/AKT/C-Jun and C-Myc and Promotes Cell Growth in Nasopharyngeal Carcinoma

Overview
Journal Cell Death Dis
Date 2013 May 18
PMID 23681229
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Connective tissue growth factor (CTGF) has different roles in different types of cancer. However, the involvement and molecular basis of CTGF in tumor progression and prognosis of human nasopharyngeal carcinoma (NPC) have almost never been reported. In this study, we observed that downregulated CTGF expression was significantly associated with NPC progression and poor prognosis. Knockdown of CTGF markedly elevated the ability of cell proliferation in vivo and in vitro. Subsequently, we discovered that the reduction of CTGF increased the expression of miR-18b, an oncomir-promoting cell proliferation. Further, we discovered that attenuated CTGF-mediated upregulation of miR-18b was dependent on the increased binding of transcription factors Jun proto-oncogene (C-Jun) and v-Myc myelocytomatosis viral oncogene homolog (C-Myc) to miR-18b promoter region via phosphoinositide 3-kinase (PI3K)/AKT pathway. Finally, we further found that miR-18b directly suppressed the expression of CTGF in NPC. In clinical fresh specimens, miR-18b was widely overexpressed and inversely correlated with CTGF expression in NPC. Our studies are the first to demonstrate that reduced CTGF as an unfavorable prognosis factor mediates the activation of miR-18b, an oncomir directly suppresses CTGF expression, by PI3K/AKT/C-Jun and C-Myc and promotes cell growth of NPC.

Citing Articles

Downregulated CCND3 Is a Key Event Driving Lung Adenocarcinoma Metastasis during Acquired Cisplatin Resistance.

Su Y, Ma Y, Wang Y, Xu P, Guo M, Cao H Int J Biol Sci. 2025; 21(2):708-724.

PMID: 39781469 PMC: 11705650. DOI: 10.7150/ijbs.100921.


Increased expression is a potential unfavourable factor promoting the growth of nasopharyngeal carcinoma.

Wu S, Peng L J Int Med Res. 2024; 52(9):3000605241271754.

PMID: 39286844 PMC: 11409311. DOI: 10.1177/03000605241271754.


Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases.

Fu M, Peng D, Lan T, Wei Y, Wei X Acta Pharm Sin B. 2022; 12(4):1740-1760.

PMID: 35847511 PMC: 9279711. DOI: 10.1016/j.apsb.2022.01.007.


Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop.

Wang Y, Yan Q, Mo Y, Liu Y, Wang Y, Zhang S Mol Cancer. 2022; 21(1):62.

PMID: 35227262 PMC: 8883650. DOI: 10.1186/s12943-022-01502-2.


The emerging roles of exosomal miRNAs in nasopharyngeal carcinoma.

Liao C, Liu H, Luo X Am J Cancer Res. 2021; 11(6):2508-2520.

PMID: 34249413 PMC: 8263644.


References
1.
Chien W, OKelly J, Lu D, Leiter A, Sohn J, Yin D . Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol. 2011; 38(6):1741-7. PMC: 3711677. DOI: 10.3892/ijo.2011.985. View

2.
Alajez N, Shi W, Hui A, BRUCE J, Lenarduzzi M, Ito E . Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis. 2011; 1:e85. PMC: 3035896. DOI: 10.1038/cddis.2010.64. View

3.
Yang F, Tuxhorn J, Ressler S, McAlhany S, Dang T, Rowley D . Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005; 65(19):8887-95. DOI: 10.1158/0008-5472.CAN-05-1702. View

4.
Bennewith K, Huang X, Ham C, Graves E, Erler J, Kambham N . The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 2009; 69(3):775-84. PMC: 2747032. DOI: 10.1158/0008-5472.CAN-08-0987. View

5.
Landi M, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen A . MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010; 16(2):430-41. PMC: 3163170. DOI: 10.1158/1078-0432.CCR-09-1736. View